Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

October 03, 2025

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.

Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén, Joacim Malmqvist and Rebecka Björnestedt.

Related

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

 Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Nordisk Ytbehandling

 Vinge has advised Revivo Group in connection with the acquisition of Nordisk Ytbehandling, a well-established contracting company based in Nyköping specialising in blasting as well as anti-corrosion and fire protection painting, with a solid customer base within the industrial and infrastructure sectors.
December 19, 2025

Vinge advises on the sale of NCS Colour

 Vinge has advised Sobro and other owners in conjunction with Helix Kapital becoming a new owner partner in NCS Colour, together with the management team.
December 19, 2025